What Are Ipamorelin and CJC-1295? The Two Doors to the Growth-Hormone Axis

The pituitary gland keeps a strange schedule. Rather than dribbling growth hormone steadily into the blood, it fires it in bursts — sharp pulses, mostly at night, separated by long quiet troughs. For decades, researchers chasing this rhythm faced a frustrating trade-off: the molecules that reliably triggered a pulse also pulled cortisol, prolactin and hunger along for the ride. Then, in the late 1990s, two different design philosophies converged on the same axis from two different directions. One molecule learned to imitate ghrelin, the hormone of hunger. The other learned to imitate GHRH, the pituitary’s own release signal. Studied as a pair ever since, Ipamorelin and CJC-1295 are two keys cut for two different locks on the same door.

What are Ipamorelin and CJC-1295?

Both are synthetic peptides; both are studied for how they nudge the growth-hormone (GH) axis; and that is roughly where the similarity ends. Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide that acts as a ghrelin mimetic, binding the growth-hormone secretagogue receptor GHSR-1a. When Raun and colleagues first characterised it in 1998, they made a striking claim: it was the first selective growth-hormone secretagogue, prompting a clean GH release in animal models without the spillover of adrenocorticotropin, cortisol or prolactin that dogged earlier secretagogues such as GHRP-6¹⁰. Selectivity, not raw potency, was the headline.

CJC-1295 takes the other route. It is a long-acting analog of GHRH — growth-hormone-releasing hormone — built on the GRF(1-29) fragment and stabilised against rapid breakdown. In studies of normal adults, it activated the GH/IGF-1 axis and shifted serum protein profiles consistent with that activation⁵. The chemistry behind these stabilised GHRH fragments traces back to careful work on site-specific modification of GRF(1-29)⁶. Where Ipamorelin imitates the hunger hormone, CJC-1295 imitates the pituitary’s own “release now” instruction.

How does the GH/IGF-1 axis actually work?

Think of the axis as a relay. The hypothalamus sends two opposing signals to the pituitary: GHRH says “release,” somatostatin says “hold.” Ghrelin, produced mainly in the stomach, adds a third voice that also pushes for release. The pituitary integrates these and fires GH in pulses; GH then travels to the liver and other tissues, where much of its downstream signalling is carried out by insulin-like growth factor 1 (IGF-1). This is why two different molecules can raise the same output. Ipamorelin works through the ghrelin/GHSR-1a channel; CJC-1295 works through the GHRH channel. They are studied together precisely because they pull different levers on one shared machine.

Two secretagogues, two receptors: the reason researchers almost always study them as a complementary pair rather than in isolation.

CJC-1295 with and without DAC: one backbone, two durations

Two different products are sold under the name CJC-1295, and the difference lives in four letters. Both are analogues of the N-terminal 29-residue fragment of GHRH, known as modified GRF(1-29), with substitutions (notably D-Ala at position 2) that resist enzymatic cleavage.¹⁶ Native GHRH is degraded in plasma within minutes by dipeptidyl peptidase-IV and trypsin-like enzymes acting at the N-terminus.¹⁷ The substitution blunts that first cut, but the bare peptide still clears quickly. The DAC (drug affinity complex) is a maleimidopropionyl group that binds serum albumin covalently, turning a carrier protein into a slow-release depot; this was demonstrated with hGRF(1-29)-albumin bioconjugates on the rat pituitary GRF receptor.¹⁸ The DAC changes how long the molecule lingers, not which receptor it targets.

The human pharmacokinetics of the DAC form were characterised in two randomised, placebo-controlled ascending-dose studies in healthy adults: a single administration produced dose-dependent increases in mean plasma GH of roughly two- to ten-fold lasting six days or more, and in mean IGF-1 of about 1.5- to three-fold lasting nine to eleven days, with an estimated half-life of 5.8 to 8.1 days.¹⁹ The no-DAC peptide, lacking the albumin anchor, does not have that window.

Specifications are supplier reference data; half-life figures describe published experimental observations, not guidance for use.

The no-DAC form exists because a shorter, sharper kinetic profile is sometimes the point of an experiment. The pituitary releases GH in bursts and the pattern of exposure is itself a biological variable, so a week-long albumin-tethered stimulus is a substantial departure from the native rhythm. Even under continuous DAC stimulation, pulsatile GH secretion has been reported to persist because somatostatin tone still gates the pituitary.⁷ The co-formulated Condor Research blend uses the no-DAC form, so the earlier comparison table, which describes the DAC variant, should not be read as describing that blend.

The human record for either form is narrow: a few early-phase reports in healthy volunteers describing GH and IGF-1 responses and pharmacokinetics, with no long-term safety profile, no outcome in any disease population and no published head-to-head human comparison of the two forms. As GHRH analogues, both fall under category S2 of the WADA framework, and dedicated mass-spectrometric detection methods exist for GHRH-class peptides.²⁰

What does the research record show?

One of the most counter-intuitive findings concerns rhythm. You might expect that a long-acting stimulus would flatten the pituitary’s natural bursts into a steady drone. It does not. Ionescu and Frohman showed that pulsatile GH secretion persists even during continuous stimulation by CJC-1295⁷ — the pituitary keeps its own beat, raising the baseline without erasing the pulses. In the GHRH-knockout mouse, once-daily CJC-1295 was enough to normalise growth⁸, a clean demonstration that the analog substitutes for the missing native signal.

Ipamorelin’s record reaches into territory that has little to do with growth at all. Early pharmacokinetic work mapped its absorption, including a study of nasal absorption of GH secretagogues⁹. Because GHSR-1a is expressed in the gut as well as the brain, several models examined gastrointestinal motility: Ipamorelin was studied against gastric dysmotility in a rodent postoperative-ileus model¹⁵, and a randomised proof-of-concept trial examined it for postoperative ileus in patients undergoing bowel resection¹⁴. Related GHSR-1a agonists, including Ipamorelin, have also been studied for their effect on cisplatin-induced weight loss in ferrets¹¹, and Ipamorelin’s interaction with the hypothalamic-pituitary-testicular axis has been probed in a cichlid fish¹². The picture that emerges is of a molecule whose biology spills well beyond the pituitary.

Where did the ghrelin receptor and ipamorelin come from?

The history runs backwards. A pituitary and hypothalamic receptor that functions in growth-hormone release was cloned in 1996, before anyone knew its natural ligand, and was in effect discovered through the synthetic secretagogues that activated it.²¹ Its endogenous ligand, the acylated stomach peptide ghrelin, was identified three years later.²² Ipamorelin belongs to this ghrelin-mimetic branch, not to the releasing-hormone branch that CJC-1295 represents.

Because the receptor sits at a crossroads of GH release, appetite and gastrointestinal motility, ghrelin-receptor agonists as a class have been studied for several distinct purposes, from cancer-related cachexia to disordered gut motility, not solely for GH output.²³²⁴ In adult female rats, ipamorelin and GHRP-6 were reported to increase bone mineral content, a result consistent with chronic stimulation of the GH/IGF-1 axis.²⁵ That is a real preclinical signal, and also a good illustration of the evidentiary gap: a bone-density change in rats is exactly the kind of observation routinely and wrongly translated into human claims. Ipamorelin also showed markedly lower systemic clearance than GHRP-6 in the early pharmacokinetic work.⁹

Same axis, different molecules: 711.85 versus 3,367.9 g/mol.

Reviews of the GH-secretagogue class as a whole make the same point: while the mechanism is well understood and several agents have been studied in humans, the evidence for the “anti-ageing”, body-composition and recovery claims attached to them on the grey market is weak, and long-term safety in healthy adults is not established.²⁶ The “selective” label describes a narrow technical property, which hormones the molecule does and does not provoke in the founding study, not whether it produces a meaningful effect in a living organism.

Why do these peptides appear so often in anti-doping research?

If you search the literature, a large share of the published work on CJC-1295 is not about endocrinology at all — it is about detection. Analysts have confirmed CJC-1295 in equine plasma by LC-MS/MS², developed immuno-PCR screens for CJC-1295 and related GHRH analogs³, and even identified CJC-1295 inside an unknown, unlabelled pharmaceutical preparation⁴. Ipamorelin shows up in the same world: studies have tracked GH-releasing-peptide metabolites in human urine after nasal administration of several secretagogues including Ipamorelin¹³. There is even sociological work — a netnographic study of how CJC-1295 circulates in certain online communities¹. Both peptides are prohibited in sport at all times, which is precisely why so much analytical effort has gone into confirming and screening for them in plasma and urine²³⁴¹³.

How strong is the human evidence?

Here honesty matters more than enthusiasm. The body of work on Ipamorelin and CJC-1295 is dominated by pharmacology, animal models and analytical detection — receptor binding, rodent and fish studies, equine plasma assays, knockout-mouse rescue experiments. Genuine human clinical evidence is limited. The CJC-1295 work in normal adults⁵ and the postoperative-ileus proof-of-concept trial¹⁴ are real human data points, but they are early-stage and narrow; they do not amount to a settled clinical profile. Much of what circulates publicly outpaces what has actually been demonstrated in controlled human research. A careful reader treats these as research compounds with an interesting but unfinished evidence base, not as established interventions.

Research-use-only: why identity and purity decide everything

For peptides like these, the science is only as trustworthy as the material in the vial. The detection literature itself makes the point: CJC-1295 has been found inside preparations whose contents were otherwise unknown⁴. A study run on a mislabelled or impure peptide is not a study of that peptide at all. That is why verified identity, documented purity and a batch-specific Certificate of Analysis (COA) are not paperwork — they are preconditions for any result to mean anything.

To be unambiguous: Ipamorelin and CJC-1295 are supplied strictly as Research Use Only materials. They are not medicines, are not for human or veterinary use, and nothing here is dosing, protocol or administration guidance. Any figures reported in the studies cited above describe what those specific animal models or in-vitro systems used — never a recommendation for a person. For researchers working across the metabolic and longevity space, the same standard applies to neighbouring compounds such as Retatrutide and Epitalon: the evidence is the experiment, and the experiment is only as good as the molecule it was run on.